3-nitropropionic acid has been researched along with Huntington Disease in 231 studies
3-nitropropionic acid: succinate dehydrogenase inactivator; biosynthesized by FABACEAE plants from ASPARAGINE
3-nitropropanoic acid : A C-nitro compound that is propanoic acid in which one of the methyl hydrogens has been replaced by a nitro group.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Reactive astrocytosis seems to be strongly implicated in the development and maintenance of inflammatory and neurodegenerative disorders." | 5.36 | Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats. ( Bianco, MR; Cirillo, G; Maggio, N; Papa, M; Sellitti, S; Vollono, C, 2010) |
| "L-theanine is unique amino acid which readily crosses blood brain barrier and possesses neuroprotective potential against neurodegenerative disorders including Huntington disease (HD)." | 3.85 | L-theanine, a Component of Green Tea Prevents 3-Nitropropionic Acid (3-NP)-Induced Striatal Toxicity by Modulating Nitric Oxide Pathway. ( Jamwal, S; Kumar, P, 2017) |
| "This study was designed to evaluate the effects of bis selenide on Huntington disease (HD)-like signs induced by 3-nitropropionic acid (3-NP) in rats." | 3.79 | Organoselenium bis selenide attenuates 3-nitropropionic acid-induced neurotoxicity in rats. ( Bortolatto, CF; Chagas, PM; Jesse, CR; Nogueira, CW; Wilhelm, EA, 2013) |
| " The injections of MitoTracker Red CM-H(2)XRos revealed generation of mitochondrial free radicals primarily in vulnerable neurons following focal cerebral ischemia as well as administration of Fe(2+) or 3-nitropropionic acid." | 3.71 | Analysis of mitochondrial free radical generation in animal models of neuronal disease. ( Gwag, BJ; Kim, DY; Won, SJ, 2002) |
| " Remarkably, in a rat model of Huntington's disease generated by subcutaneous infusion of the mitochondrial inhibitor 3-nitropropionic acid (3NP), we have observed that an acute treatment with ADAC (100 microg x kg(-1) x d(-1)) not only strongly reduces the size of the striatal lesion (-40%) and the remaining ongoing striatal degeneration (-30%), but also prevents the development of severe dystonia of hindlimbs." | 3.71 | The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. ( Bantubungi, K; Blum, D; d'Alcantara, P; Galas, MC; Gall, D; Schiffmann, SN, 2002) |
| " Neuroblastoma SH-SY5Y cells stably overexpressing human tTG or mutated inactive tTG were treated with 3-nitropropionic acid (3-NP), an irreversible inhibitor of succinate dehydrogenase." | 3.70 | Impaired mitochondrial function results in increased tissue transglutaminase activity in situ. ( Johnson, GV; Lesort, M; Tucholski, J; Zhang, J, 2000) |
| "Telmisartan was also implicated in the modulation of phosphatidyl inositol 3-kinase/protein kinase B/glycogen synthase kinase-3β (PI3K/Akt/GSK-3β) and extracellular signal-regulated kinase (ERK) 1/2 cascades with consequent anti-oxidative, anti-inflammatory, and anti-apoptotic effects." | 1.72 | Telmisartan neuroprotective effects in 3-nitropropionic acid Huntington's disease model in rats: Cross talk between PPAR-γ and PI3K/Akt/GSK-3β pathway. ( Abdel Rasheed, NO; Ibrahim, WW, 2022) |
| "Treatment with diapocynin hindered 3-NP-induced apoptosis with prominent decrease in tumor suppressor protein and Bcl-2-associated X protein contents whereas the anti-apoptotic marker; B-cell lymphoma-2 content was noticeably increased." | 1.72 | Diapocynin neuroprotective effects in 3-nitropropionic acid Huntington's disease model in rats: emphasis on Sirt1/Nrf2 signaling pathway. ( Abdel Rasheed, NO; Ibrahim, WW, 2022) |
| "Ellagic acid (EA) is a naturally derived polyphenol acknowledged for potent neuroprotective abilities that enabled its significance amongst popular brain tonics." | 1.62 | Ellagic acid prevents 3-nitropropionic acid induced symptoms of Huntington's disease. ( Bansal, N; Kumar, M; Sharma, P, 2021) |
| "Huntington's disease is an autosomal dominant, progressive, and fatal neurodegenerative disease characterized by motor and non-motor symptoms." | 1.40 | Role of neurosteroids in experimental 3-nitropropionic acid induced neurotoxicity in rats. ( Deshmukh, R; Khan, A; Kumar, P; Lal Sharma, P, 2014) |
| "Treatment with moxonidine, NDDCT and TBZ significantly attenuated 3-NPA induced reduction in body weight, locomotor activity, grip strength, anxiety as well as impaired learning and memory." | 1.40 | Pharmacological benefit of I(1)-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease. ( Gupta, S; Sharma, B, 2014) |
| "Trandolapril is a centrally active ACE inhibitor." | 1.40 | Potential of protease inhibitor in 3-nitropropionic acid induced Huntington's disease like symptoms: mitochondrial dysfunction and neurodegeneration. ( Hariharan, A; Jagtap, AG; Shetty, S; Shirole, T, 2014) |
| "Although the mutated protein causing Huntington's disease (HD) is expressed throughout the body, the major pathology of HD is localized to the striatum of the brain." | 1.39 | Rhes deletion is neuroprotective in the 3-nitropropionic acid model of Huntington's disease. ( Mealer, RG; Snyder, SH; Subramaniam, S, 2013) |
| "Quercetin was supplemented at a dose of 25mg/kg body weight by oral gavage for 21days." | 1.39 | Quercetin supplementation is effective in improving mitochondrial dysfunctions induced by 3-nitropropionic acid: implications in Huntington's disease. ( Mehrotra, A; Sandhir, R, 2013) |
| "Huntington's disease is a progressive neurodegenerative disorder that gradually reduces memory, cognitive skills and normal movements of affected individuals." | 1.38 | Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity. ( Kalonia, H; Kumar, A; Kumar, P, 2012) |
| " Our data suggest that the two studied toxic models (QA and 3-NP) or the combined model (QA plus 3-NP) can generate complex patterns of damage, which involve metabolic compromise, ROS formation, and oxidative stress." | 1.38 | Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro. ( Colle, D; Farina, M; Hartwig, JM; Soares, FA, 2012) |
| "Reactive astrocytosis seems to be strongly implicated in the development and maintenance of inflammatory and neurodegenerative disorders." | 1.36 | Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats. ( Bianco, MR; Cirillo, G; Maggio, N; Papa, M; Sellitti, S; Vollono, C, 2010) |
| "Several human neurodegenerative disorders are characterized by the accumulation of 8-oxo-7,8-dihydroguanine (8-oxodG) in the DNA of affected neurons." | 1.35 | A role for oxidized DNA precursors in Huntington's disease-like striatal neurodegeneration. ( Bignami, M; Crescenzi, M; De Luca, G; Degan, P; Mattei, E; Meccia, E; Nakabeppu, Y; Pepponi, R; Pèzzola, A; Popoli, P; Russo, MT; Tiveron, C; Ventura, I; Zijno, A, 2008) |
| "Huntington's disease is characterized by abnormal body movements (chorea) and cognitive dysfunctions." | 1.35 | Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations. ( Kumar, A; Kumar, P, 2009) |
| " Chronic administration of W." | 1.35 | Possible neuroprotective effect of Withania somnifera root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Huntington's disease. ( Kumar, A; Kumar, P, 2009) |
| "Huntington's disease is an incurable, adult-onset, dominantly inherited neurodegenerative disease." | 1.35 | Tiagabine, a GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats. ( Akula, KK; Dhir, A; Kulkarni, SK, 2008) |
| "In patients with Huntington's disease (HD), the proteolytic activity of the ubiquitin proteasome system (UPS) is reduced in the brain and other tissues." | 1.34 | Proteasome activator enhances survival of Huntington's disease neuronal model cells. ( Cattaneo, E; Isacson, O; Kim, W; Seo, H; Sonntag, KC, 2007) |
| "However, its potential in Huntington's disease (HD) models characterized by calpain-dependent degeneration and inflammation has not been investigated." | 1.33 | Minocycline in phenotypic models of Huntington's disease. ( Bantubungi, K; Blum, D; Brotchi, J; Brouillet, E; Chtarto, A; Déglon, N; Galas, MC; Greco, A; Jacquard, C; Levivier, M; Minghetti, L; Pintor, A; Popoli, P; Schiffmann, SN; Tai, K; Tenenbaum, L, 2005) |
| "In summary, arvanil does alleviate hyperkinesia typical of HD, although it also affects locomotion in normal rats." | 1.33 | Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease. ( de Lago, E; Di Marzo, V; Fernández-Ruiz, J; Ramos, JA; Urbani, P, 2005) |
| "In the pathogenesis of Parkinson's disease and Huntington's disease excitotoxicity may play an important role." | 1.33 | Effects of mitochondrial toxins on the brain amino acid concentrations. ( Hartai, Z; Juhasz, G; Kekesi, KA; Klivenyi, P; Vecsei, L, 2005) |
| "Huntington's disease is a progressive, degenerative disease characterized by abnormal body movements called chorea, and a reduction of various mental abilities." | 1.33 | Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. ( Kumar, A; Kumar, P; Naidu, PS; Padi, SS, 2006) |
| "Huntington's disease has an increase in the activated calpain, which is enhanced by the NMDA receptor activation." | 1.33 | Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease. ( Chu, K; Jung, KH; Kang, L; Kim, M; Ko, SY; Lee, ST; Park, JE, 2006) |
| "Taurine pretreatment also caused about 2-fold increase in GABA concentration compared to 3-NP-treated animals." | 1.33 | Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype. ( Abdel-Naim, AB; Arafa, HM; Khalifa, AE; Tadros, MG, 2005) |
| "Age of onset of Huntington's disease (HD) statistically correlates with the length of expanded CAG repeats in the IT15 gene." | 1.32 | Experimental basis for the putative role of GluR6/kainate glutamate receptor subunit in Huntington's disease natural history. ( Centelles, L; Diguet, E; Fernagut, PO; Mulle, C; Normand, E; Tison, F, 2004) |
| "The precise cause of neuronal death in Huntington's disease (HD) is unknown." | 1.32 | Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. ( Beesen, A; Ferrante, RJ; Hersch, SM; Kowall, NW; Kubilus, JK; Lee, J; Luthi-Carter, R; Ratan, RR; Ryu, H; Smith, K; Zucker, B, 2003) |
| "Striatal cell death in Huntington's Disease (HD) may involve mitochondrial defects, NMDA-mediated excitotoxicity, and activation of death effector proteases such as caspases and calpain." | 1.32 | Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. ( Bizat, N; Boyer, F; Brouillet, E; Créminon, C; Escartin, C; Hantraye, P; Hermel, JM; Jacquard, C; Kajewski, S; Ouary, S, 2003) |
| "An important aspect of Huntington's disease (HD) pathogenesis which may have important therapeutic implications is that the cellular events leading to cell death may be different in cortical and striatal neurons." | 1.32 | Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms. ( Bantubungi, K; Bizat, N; Blum, D; Brouillet, E; Cuvelier, L; Galas, MC; Schiffmann, SN, 2004) |
| "To investigate the effects of time interval and cumulative dosage of repetitive mild cellular hypoxia on shape of neurodegeneration and neuroprotection in mice, population spike amplitude (PSA) was measured during hypoxia and posthypoxic recovery in hippocampal slices from untreated control and mice pretreated in vivo with a single or repeatedly intraperitoneal injection of 3-nitropropionate (3-NP)." | 1.31 | Increased neuronal hypoxic tolerance induced by repetitive chemical hypoxia. ( Li, H; Liu, C; Sun, S, 2002) |
| "In adult-onset Huntington's disease (HD), striatal projection neurons are much more vulnerable than striatal interneurons, but even striatal projection neurons show differences in their vulnerability, with the striatal projection neurons projecting to the internal segment of the globus pallidus being the least vulnerable." | 1.31 | The differential vulnerability of striatal projection neurons in 3-nitropropionic acid-treated rats does not match that typical of adult-onset Huntington's disease. ( Reiner, A; Sun, Z; Xie, J, 2002) |
| "Neuronal loss in Huntington's disease (HD) is seen first in the neostriatum." | 1.31 | Mice transgenic for the Huntington's disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity. ( Hickey, MA; Morton, AJ, 2000) |
| "Ursodeoxycholic acid (UDCA) has been shown to be a strong modulator of the apoptotic threshold in both hepatic and nonhepatic cells." | 1.31 | Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition. ( Keene, CD; Kren, BT; Low, WC; Ma, X; Rodrigues, CM; Steer, CJ; Stieers, CL, 2000) |
| "Huntington's disease is a progressive neurodegenerative disease characterized by movement disorder, cognitive deterioration, and selective striatal degeneration." | 1.31 | Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease. ( Emborg, ME; Kordower, JH; Palfi, S; Roitberg, BZ; Sramek, JG, 2002) |
| " Chronic administration of 3-nitropropionic acid (3-NP), a suicide inhibitor of succinate dehydrogenase, causes prolonged energy impairments and replicates most of the pathophysiological features of HD, including preferential striatal degeneration." | 1.31 | The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase/c-Jun module. ( Besson, MJ; Brouillet, E; Caboche, J; Garcia, M; Pages, C; Vanhoutte, P, 2002) |
| "Animals with these Huntington's disease-like lesions showed spontaneous motor symptoms including mild dystonia, bradykinesia and gait abnormalities, which were barely detectable on visual inspection but could be readily identified and quantified by computerized video analysis." | 1.30 | Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. ( Brouillet, E; Dolan, R; Guyot, MC; Hantraye, P; Maziére, M; Palfi, S, 1997) |
| "The gene defect in Huntington's disease (HD) may result in an impairment of energy metabolism." | 1.30 | Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. ( Beal, MF; Ferrante, RJ; Jenkins, BG; Kaddurah-Daouk, R; Matthews, RT; Rosen, BR; Yang, L, 1998) |
| "Huntington's disease is a progressive neurodegenerative disorder associated with severe degeneration of basal ganglia neurons, especially the intrinsic neurons of the striatum, and characterized by involuntary abnormal choreiform movements and progressive dementia." | 1.29 | Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease. ( Borlongan, CV; Cahill, DW; Freeman, TB; Koutouzis, TK; Sanberg, PR, 1995) |
| "We showed recently that chronic administration of the mitochondrial inhibitor 3-nitropropionic acid (3NP) in primates produces various dyskinetic movements and dystonic postures associated with selective striatal lesions displaying many similarities with the pathological features of Huntington's disease (HD)." | 1.29 | Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. ( Beal, MF; Brouillet, E; Dolan, R; Ferrante, RJ; Guyot, MC; Hantraye, P; Palfi, S; Peschanski, M, 1996) |
| "Animals showed both choreiform movements, as well as foot and limb dystonia, which are characteristic of HD." | 1.29 | Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. ( Beal, MF; Brouillet, E; Dolan, R; Ferrante, RJ; Hantraye, P; Kowall, NW; Leroy-Willig, A, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (9.52) | 18.2507 |
| 2000's | 102 (44.16) | 29.6817 |
| 2010's | 83 (35.93) | 24.3611 |
| 2020's | 24 (10.39) | 2.80 |
| Authors | Studies |
|---|---|
| Okada, N | 2 |
| Yako, T | 1 |
| Nakamura, S | 2 |
| Shimazawa, M | 2 |
| Hara, H | 1 |
| Alshehri, S | 2 |
| Al-Abbasi, FA | 2 |
| Ghoneim, MM | 1 |
| Imam, SS | 2 |
| Afzal, M | 1 |
| Alharbi, KS | 1 |
| Nadeem, MS | 1 |
| Sayyed, N | 2 |
| Kazmi, I | 2 |
| Senousy, MA | 1 |
| Hanafy, ME | 1 |
| Shehata, N | 1 |
| Rizk, SM | 1 |
| Abdel Rasheed, NO | 2 |
| Ibrahim, WW | 2 |
| El-Shamarka, ME | 1 |
| El-Sahar, AE | 1 |
| Saad, MA | 2 |
| Assaf, N | 1 |
| Sayed, RH | 1 |
| Habib, MZ | 1 |
| Tadros, MG | 4 |
| Abd-Alkhalek, HA | 1 |
| Mohamad, MI | 1 |
| Eid, DM | 1 |
| Hassan, FE | 1 |
| Elhelaly, H | 1 |
| Faramawy, YE | 1 |
| Aboul-Fotouh, S | 1 |
| Kadir, A | 1 |
| Singh, J | 1 |
| Rahi, V | 5 |
| Kumar, P | 19 |
| Ram, P | 3 |
| Gendy, AM | 1 |
| El-Sadek, HM | 1 |
| Amin, MM | 1 |
| Ahmed, KA | 1 |
| El-Sayed, MK | 1 |
| El-Haddad, AE | 1 |
| Soubh, A | 1 |
| Upadhayay, S | 1 |
| Yedke, NG | 1 |
| Singh, S | 2 |
| Kumar, S | 1 |
| Arora, A | 1 |
| Chandolia, P | 1 |
| Kaur, P | 1 |
| Kumar, M | 2 |
| Koshal, P | 1 |
| Jamwal, S | 2 |
| Mahdi, WA | 1 |
| AlGhamdi, SA | 1 |
| Alghamdi, AM | 1 |
| Almaniea, MA | 1 |
| Hajjar, BM | 1 |
| Sayed, NH | 1 |
| Fathy, N | 1 |
| Kortam, MA | 1 |
| Rabie, MA | 1 |
| Mohamed, AF | 1 |
| Kamel, AS | 1 |
| Moslemi, M | 1 |
| Khodagholi, F | 3 |
| Asadi, S | 1 |
| Rafiei, S | 1 |
| Motamedi, F | 1 |
| Subramaniam, S | 2 |
| Yang, X | 1 |
| Chu, SF | 2 |
| Wang, ZZ | 2 |
| Li, FF | 1 |
| Yuan, YH | 1 |
| Chen, NH | 2 |
| Ahmed, S | 1 |
| Kwatra, M | 1 |
| Gawali, B | 1 |
| Panda, SR | 1 |
| Naidu, VGM | 1 |
| Eskandari, N | 2 |
| Boroujeni, ME | 2 |
| Abdollahifar, MA | 3 |
| Piryaei, A | 1 |
| Mirbehbahani, SH | 1 |
| Siroosi, S | 1 |
| Moghaddam, MH | 2 |
| Aliaghaei, A | 3 |
| Sadeghi, Y | 2 |
| Fotoohi, A | 1 |
| Moloudi, MR | 1 |
| Hosseini, S | 1 |
| Hassanzadeh, K | 1 |
| Feligioni, M | 1 |
| Izadpanah, E | 1 |
| Bayat, AH | 1 |
| Fotouhi, F | 1 |
| Forouzannia, A | 1 |
| Rafiei, R | 1 |
| Hatari, S | 1 |
| Seraj, A | 1 |
| Shahidi, AMEJ | 1 |
| Ghorbani, Z | 1 |
| Peyvandi, AA | 1 |
| Sharma, P | 1 |
| Bansal, N | 1 |
| Ahmed, MAE | 1 |
| Elbadawy, NN | 1 |
| Abdelkader, NF | 1 |
| Silva-Palacios, A | 2 |
| Colín-González, AL | 1 |
| López-Cervantes, SP | 1 |
| Zazueta, C | 2 |
| Luna-López, A | 2 |
| Santamaría, A | 4 |
| Königsberg, M | 2 |
| Ostolga-Chavarría, M | 1 |
| Buelna-Chontal, M | 1 |
| Garibay, C | 1 |
| Hernández-Reséndiz, S | 1 |
| Roldán, FJ | 1 |
| Flores, PL | 1 |
| Nadal, X | 1 |
| Del Río, C | 1 |
| Casano, S | 1 |
| Palomares, B | 1 |
| Ferreiro-Vera, C | 1 |
| Navarrete, C | 2 |
| Sánchez-Carnerero, C | 1 |
| Cantarero, I | 2 |
| Bellido, ML | 2 |
| Meyer, S | 1 |
| Morello, G | 1 |
| Appendino, G | 1 |
| Muñoz, E | 2 |
| Gómez-Pineda, VG | 1 |
| Torres-Cruz, FM | 1 |
| Vivar-Cortés, CI | 1 |
| Hernández-Echeagaray, E | 3 |
| Ebrahimi, MJ | 1 |
| Meftahi, G | 1 |
| Ahmadi, H | 1 |
| Danyali, S | 1 |
| Daftari, M | 1 |
| Ramachandran, S | 3 |
| Thangarajan, S | 3 |
| Danduga, RCSR | 1 |
| Dondapati, SR | 1 |
| Kola, PK | 1 |
| Grace, L | 1 |
| Tadigiri, RVB | 1 |
| Kanakaraju, VK | 1 |
| Sidhu, A | 1 |
| Diwan, V | 1 |
| Kaur, H | 1 |
| Bhateja, D | 1 |
| Singh, CK | 1 |
| Sharma, S | 2 |
| Padi, SSV | 1 |
| El-Abhar, H | 1 |
| Abd El Fattah, MA | 1 |
| Wadie, W | 1 |
| El-Tanbouly, DM | 1 |
| Abdelfattah, MS | 1 |
| Badr, SEA | 1 |
| Lotfy, SA | 1 |
| Attia, GH | 1 |
| Aref, AM | 1 |
| Abdel Moneim, AE | 1 |
| Kassab, RB | 1 |
| Mealer, RG | 1 |
| Snyder, SH | 1 |
| Shivasharan, BD | 1 |
| Nagakannan, P | 2 |
| Thippeswamy, BS | 2 |
| Veerapur, VP | 2 |
| Bansal, P | 1 |
| Unnikrishnan, MK | 1 |
| Colle, D | 2 |
| Santos, DB | 1 |
| Moreira, EL | 1 |
| Hartwig, JM | 2 |
| dos Santos, AA | 1 |
| Zimmermann, LT | 1 |
| Hort, MA | 1 |
| Farina, M | 2 |
| Sandhir, R | 6 |
| Yadav, A | 1 |
| Mehrotra, A | 6 |
| Sunkaria, A | 1 |
| Singh, A | 1 |
| Pereira, GJ | 1 |
| Tressoldi, N | 1 |
| Hirata, H | 1 |
| Bincoletto, C | 1 |
| Smaili, SS | 1 |
| Binawade, Y | 1 |
| Jagtap, A | 1 |
| Chakraborty, J | 3 |
| Singh, R | 1 |
| Dutta, D | 1 |
| Naskar, A | 1 |
| Rajamma, U | 3 |
| Mohanakumar, KP | 5 |
| Kudo, T | 1 |
| Loh, DH | 1 |
| Tahara, Y | 1 |
| Truong, D | 1 |
| Colwell, CS | 1 |
| Khan, A | 1 |
| Deshmukh, R | 1 |
| Lal Sharma, P | 1 |
| Nthenge-Ngumbau, DN | 1 |
| Gupta, S | 3 |
| Sharma, B | 3 |
| Souza, LC | 1 |
| Wilhelm, EA | 2 |
| Bortolatto, CF | 2 |
| Nogueira, CW | 2 |
| Boeira, SP | 1 |
| Jesse, CR | 2 |
| Fink, KD | 2 |
| Crane, AT | 1 |
| Lévêque, X | 2 |
| Dues, DJ | 1 |
| Huffman, LD | 1 |
| Moore, AC | 1 |
| Story, DT | 1 |
| Dejonge, RE | 1 |
| Antcliff, A | 1 |
| Starski, PA | 1 |
| Lu, M | 1 |
| Lescaudron, L | 2 |
| Rossignol, J | 2 |
| Dunbar, GL | 3 |
| Brouillet, E | 21 |
| Valdeolivas, S | 1 |
| Sagredo, O | 1 |
| Pandey, M | 3 |
| Navneet, AK | 2 |
| Appukuttan, TA | 1 |
| Varghese, M | 3 |
| Sreetama, SC | 1 |
| Kannike, K | 1 |
| Sepp, M | 1 |
| Zuccato, C | 1 |
| Cattaneo, E | 2 |
| Timmusk, T | 1 |
| Török, R | 1 |
| Kónya, JA | 1 |
| Zádori, D | 1 |
| Veres, G | 1 |
| Szalárdy, L | 1 |
| Vécsei, L | 3 |
| Klivényi, P | 7 |
| Hariharan, A | 1 |
| Shetty, S | 1 |
| Shirole, T | 1 |
| Jagtap, AG | 1 |
| Gao, Y | 1 |
| Li, JP | 1 |
| Zhang, Z | 1 |
| Yan, JQ | 1 |
| Wen, ZL | 1 |
| Xia, CY | 1 |
| Mou, Z | 1 |
| He, WB | 1 |
| Guo, XF | 1 |
| Wei, GN | 1 |
| Kaur, M | 1 |
| Prakash, A | 1 |
| Kalia, AN | 1 |
| Kanwal, A | 1 |
| Banerjee, SK | 1 |
| Sood, A | 2 |
| Menze, ET | 1 |
| Esmat, A | 1 |
| Khalifa, AE | 3 |
| Abdel-Naim, AB | 2 |
| Dhadde, SB | 1 |
| Roopesh, M | 1 |
| Anand Kumar, SR | 1 |
| Badami, S | 1 |
| Skillings, EA | 1 |
| Morton, AJ | 3 |
| Orozco-Ibarra, M | 1 |
| García-Morales, J | 1 |
| Calvo-Silva, FJ | 1 |
| Fernández-Valverde, F | 1 |
| Serrano-García, N | 1 |
| Krishnamurthy, P | 1 |
| Suganya, SN | 1 |
| Sumathi, T | 1 |
| Wang, L | 1 |
| Wang, J | 1 |
| Yang, L | 4 |
| Zhou, SM | 1 |
| Guan, SY | 1 |
| Yang, LK | 1 |
| Shi, QX | 1 |
| Zhao, MG | 1 |
| Yang, Q | 1 |
| Malik, J | 1 |
| Karan, M | 1 |
| Dogra, R | 1 |
| He, Y | 1 |
| Akumuo, RC | 1 |
| Yang, Y | 1 |
| Hewett, SJ | 1 |
| Oláh, J | 1 |
| Gardián, G | 2 |
| Orosz, F | 1 |
| Kovacs, GG | 1 |
| Westerhoff, HV | 1 |
| Ovádi, J | 1 |
| Pelegrí, C | 4 |
| Duran-Vilaregut, J | 4 |
| del Valle, J | 4 |
| Crespo-Biel, N | 2 |
| Ferrer, I | 1 |
| Pallàs, M | 6 |
| Camins, A | 6 |
| Vilaplana, J | 4 |
| Acevedo-Torres, K | 1 |
| Berríos, L | 1 |
| Rosario, N | 1 |
| Dufault, V | 1 |
| Skatchkov, S | 1 |
| Eaton, MJ | 1 |
| Torres-Ramos, CA | 1 |
| Ayala-Torres, S | 1 |
| Park, JE | 4 |
| Lee, ST | 4 |
| Im, WS | 3 |
| Chu, K | 4 |
| Kim, M | 4 |
| Canudas, AM | 1 |
| De Luca, G | 2 |
| Russo, MT | 2 |
| Degan, P | 2 |
| Tiveron, C | 1 |
| Zijno, A | 1 |
| Meccia, E | 1 |
| Ventura, I | 2 |
| Mattei, E | 1 |
| Nakabeppu, Y | 1 |
| Crescenzi, M | 1 |
| Pepponi, R | 1 |
| Pèzzola, A | 1 |
| Popoli, P | 3 |
| Bignami, M | 2 |
| Pérez-De La Cruz, V | 3 |
| Elinos-Calderón, D | 1 |
| Robledo-Arratia, Y | 1 |
| Medina-Campos, ON | 1 |
| Pedraza-Chaverrí, J | 1 |
| Ali, SF | 1 |
| Tsang, TM | 1 |
| Haselden, JN | 1 |
| Holmes, E | 1 |
| Misiak, M | 1 |
| Beyer, C | 1 |
| Arnold, S | 1 |
| Kraft, JC | 1 |
| Osterhaus, GL | 1 |
| Ortiz, AN | 1 |
| Garris, PA | 1 |
| Johnson, MA | 2 |
| Borah, A | 1 |
| Barman, PK | 1 |
| Usha, R | 2 |
| Kumar, A | 11 |
| Calingasan, NY | 3 |
| Wille, EJ | 1 |
| Cormier, K | 1 |
| Smith, K | 2 |
| Ferrante, RJ | 10 |
| Beal, MF | 12 |
| Kalonia, H | 7 |
| Tantucci, M | 1 |
| Mariucci, G | 1 |
| Taha, E | 1 |
| Spaccatini, C | 1 |
| Tozzi, A | 1 |
| Luchetti, E | 1 |
| Calabresi, P | 7 |
| Ambrosini, MV | 1 |
| Choi, YS | 1 |
| Lee, B | 1 |
| Cho, HY | 1 |
| Reyes, IB | 1 |
| Pu, XA | 1 |
| Saido, TC | 1 |
| Hoyt, KR | 1 |
| Obrietan, K | 1 |
| Niatsetskaya, Z | 1 |
| Basso, M | 2 |
| Speer, RE | 1 |
| McConoughey, SJ | 2 |
| Coppola, G | 2 |
| Ma, TC | 1 |
| Ratan, RR | 5 |
| Lagoa, R | 1 |
| Lopez-Sanchez, C | 1 |
| Samhan-Arias, AK | 1 |
| Gañan, CM | 1 |
| Garcia-Martinez, V | 1 |
| Gutierrez-Merino, C | 1 |
| Cirillo, G | 1 |
| Maggio, N | 1 |
| Bianco, MR | 1 |
| Vollono, C | 1 |
| Sellitti, S | 1 |
| Papa, M | 2 |
| Cleren, C | 1 |
| Starkov, A | 2 |
| Jacquard, C | 5 |
| Chen, J | 1 |
| Manich, G | 2 |
| Junyent, F | 2 |
| Lukács, A | 1 |
| Szabó, A | 1 |
| Papp, A | 1 |
| Vezér, T | 1 |
| Túnez, I | 6 |
| Tasset, I | 2 |
| Rodríguez, E | 1 |
| Rivera, I | 1 |
| Astorga, S | 1 |
| Mendoza, E | 1 |
| García, F | 1 |
| Wu, CL | 1 |
| Hwang, CS | 1 |
| Chen, SD | 1 |
| Yin, JH | 1 |
| Yang, DI | 1 |
| Niatsetskaya, ZV | 1 |
| Sleiman, SF | 1 |
| Smirnova, NA | 1 |
| Langley, BC | 1 |
| Mahishi, L | 1 |
| Cooper, AJ | 1 |
| Antonyak, MA | 1 |
| Cerione, RA | 1 |
| Li, B | 1 |
| Chaturvedi, RK | 1 |
| Geschwind, DH | 1 |
| Ryu, H | 3 |
| Xia, L | 1 |
| Iismaa, SE | 1 |
| Pallos, J | 1 |
| Pasternack, R | 1 |
| Hils, M | 1 |
| Fan, J | 1 |
| Raymond, LA | 1 |
| Marsh, JL | 1 |
| Thompson, LM | 1 |
| Yoon, HJ | 1 |
| Im, JY | 1 |
| Park, KH | 1 |
| Jung, KH | 2 |
| Lee, SK | 1 |
| Roh, JK | 1 |
| Boyer, C | 1 |
| Thinard, R | 1 |
| Blanchard, F | 1 |
| Mu, S | 1 |
| OuYang, L | 1 |
| Liu, B | 1 |
| Zhu, Y | 1 |
| Li, K | 1 |
| Zhan, M | 1 |
| Liu, Z | 1 |
| Jia, Y | 1 |
| Lei, W | 1 |
| Reiner, A | 2 |
| Chang, KL | 1 |
| New, LS | 1 |
| Mal, M | 1 |
| Goh, CW | 1 |
| Aw, CC | 1 |
| Browne, ER | 1 |
| Chan, EC | 1 |
| Mievis, S | 1 |
| Blum, D | 10 |
| Ledent, C | 2 |
| Fantin, M | 1 |
| Morari, M | 3 |
| Tison, F | 3 |
| Fernagut, PO | 3 |
| Rosenstock, TR | 1 |
| de Brito, OM | 1 |
| Lombardi, V | 1 |
| Louros, S | 1 |
| Ribeiro, M | 1 |
| Almeida, S | 1 |
| Ferreira, IL | 1 |
| Oliveira, CR | 1 |
| Rego, AC | 1 |
| Pontes, AJ | 1 |
| Hinojosa, AJ | 1 |
| de la Torre, R | 1 |
| Mahdy, HM | 1 |
| Mohamed, MR | 1 |
| Karim, AM | 1 |
| de Lemos, L | 1 |
| Verdaguer, E | 1 |
| Folch, J | 1 |
| Beas-Zárate, C | 1 |
| Auladell, C | 1 |
| Lim, S | 1 |
| Chesser, AS | 1 |
| Grima, JC | 1 |
| Rappold, PM | 1 |
| Przedborski, S | 1 |
| Tieu, K | 1 |
| Mochel, F | 1 |
| Durant, B | 1 |
| Meng, X | 1 |
| O'Callaghan, J | 1 |
| Yu, H | 1 |
| Wheeler, VC | 1 |
| Humbert, S | 1 |
| Schiffmann, R | 1 |
| Durr, A | 1 |
| Soares, FA | 1 |
| Kamboj, SS | 1 |
| Dastidar, SG | 1 |
| Bardai, FH | 1 |
| Ma, C | 1 |
| Price, V | 1 |
| Rawat, V | 1 |
| Verma, P | 1 |
| Narayanan, V | 1 |
| D'Mello, SR | 2 |
| Chaumeil, MM | 1 |
| Valette, J | 1 |
| Baligand, C | 1 |
| Hantraye, P | 13 |
| Bloch, G | 1 |
| Gaura, V | 1 |
| Rialland, A | 1 |
| Krystkowiak, P | 1 |
| Verny, C | 1 |
| Damier, P | 1 |
| Remy, P | 1 |
| Bachoud-Levi, AC | 1 |
| Carlier, P | 1 |
| Lebon, V | 1 |
| Sheline, CT | 1 |
| Zhu, J | 1 |
| Zhang, W | 1 |
| Shi, C | 1 |
| Cai, AL | 1 |
| Chagas, PM | 1 |
| De Nuccio, C | 1 |
| Bernardo, A | 1 |
| Visentin, S | 1 |
| Minghetti, L | 2 |
| Choi, YJ | 1 |
| Om, JY | 1 |
| Kim, NH | 1 |
| Chang, JE | 1 |
| Park, JH | 1 |
| Kim, JY | 1 |
| Lee, HJ | 1 |
| Kim, SS | 1 |
| Chun, W | 1 |
| Jovicic, A | 1 |
| Zaldivar Jolissaint, JF | 1 |
| Moser, R | 1 |
| Silva Santos, Mde F | 1 |
| Luthi-Carter, R | 2 |
| LaFontaine, MA | 1 |
| Geddes, JW | 3 |
| Butterfield, DA | 3 |
| Kim, DY | 1 |
| Won, SJ | 1 |
| Gwag, BJ | 1 |
| Galas, MC | 6 |
| Gall, D | 4 |
| Cuvelier, L | 4 |
| Schiffmann, SN | 7 |
| d'Alcantara, P | 1 |
| Bantubungi, K | 4 |
| Lastres-Becker, I | 3 |
| de Miguel, R | 2 |
| De Petrocellis, L | 1 |
| Makriyannis, A | 1 |
| Di Marzo, V | 3 |
| Fernández-Ruiz, J | 5 |
| Li, H | 1 |
| Liu, C | 1 |
| Sun, S | 1 |
| Lee, J | 2 |
| Zaman, K | 1 |
| Kubilis, J | 1 |
| Ross, BD | 1 |
| Neve, R | 1 |
| McBride, JL | 3 |
| During, MJ | 1 |
| Wuu, J | 1 |
| Chen, EY | 1 |
| Leurgans, SE | 1 |
| Kordower, JH | 4 |
| Bizat, N | 5 |
| Hermel, JM | 2 |
| Boyer, F | 3 |
| Créminon, C | 1 |
| Ouary, S | 5 |
| Escartin, C | 3 |
| Kajewski, S | 1 |
| Pintor, A | 2 |
| Muller, CE | 1 |
| Galluzzo, M | 1 |
| Rolland, AS | 1 |
| Marti, M | 2 |
| Mela, F | 1 |
| Ulazzi, L | 1 |
| Hanau, S | 1 |
| Stocchi, S | 1 |
| Paganini, F | 1 |
| Beani, L | 1 |
| Bianchi, C | 1 |
| Kubilus, JK | 1 |
| Beesen, A | 1 |
| Zucker, B | 1 |
| Kowall, NW | 2 |
| Hersch, SM | 1 |
| Saydoff, JA | 1 |
| Liu, LS | 1 |
| Garcia, RA | 1 |
| Hu, Z | 1 |
| Li, D | 1 |
| von Borstel, RW | 1 |
| Rodriguez, AI | 1 |
| Willing, AE | 1 |
| Saporta, S | 1 |
| Cameron, DF | 1 |
| Sanberg, PR | 7 |
| Saulle, E | 1 |
| Gubellini, P | 3 |
| Picconi, B | 4 |
| Centonze, D | 5 |
| Tropepi, D | 1 |
| Pisani, A | 3 |
| Rossi, L | 1 |
| Bernardi, G | 6 |
| Napolitano, M | 2 |
| Rossi, S | 2 |
| Spiezia, S | 1 |
| Gulino, A | 2 |
| Starkov, AA | 1 |
| Browne, SE | 1 |
| Bubber, P | 1 |
| Gibson, GE | 1 |
| Patel, MS | 1 |
| Diguet, E | 2 |
| Normand, E | 1 |
| Centelles, L | 1 |
| Mulle, C | 1 |
| Lee, WT | 1 |
| Chang, C | 1 |
| Wei, X | 1 |
| Du, Y | 1 |
| Rouland, R | 1 |
| Gross, C | 1 |
| Bezard, E | 1 |
| Chin, PC | 1 |
| Liu, L | 1 |
| Morrison, BE | 1 |
| Siddiq, A | 1 |
| Bottiglieri, T | 1 |
| Roberts, TJ | 2 |
| Montilla, P | 4 |
| Del Carmen Muñoz, M | 1 |
| Feijóo, M | 3 |
| Salcedo, M | 1 |
| Greco, A | 1 |
| Chtarto, A | 1 |
| Tai, K | 1 |
| Tenenbaum, L | 1 |
| Déglon, N | 2 |
| Brotchi, J | 1 |
| Levivier, M | 1 |
| Dalbem, A | 1 |
| Silveira, CV | 1 |
| Pedroso, MF | 1 |
| Breda, RV | 1 |
| Werne Baes, CV | 1 |
| Bartmann, AP | 1 |
| da Costa, JC | 1 |
| de Lago, E | 2 |
| Urbani, P | 1 |
| Ramos, JA | 4 |
| Ortega-Gutiérrez, S | 1 |
| Cabranes, A | 1 |
| Pryce, G | 1 |
| Baker, D | 1 |
| López-Rodríguez, M | 1 |
| Tariq, M | 1 |
| Khan, HA | 1 |
| Elfaki, I | 1 |
| Al Deeb, S | 1 |
| Al Moutaery, K | 1 |
| Passino, E | 1 |
| Sgobio, C | 1 |
| Bonsi, P | 2 |
| Barone, I | 1 |
| Ghiglieri, V | 1 |
| Ammassari-Teule, M | 1 |
| Arafa, HM | 1 |
| Kekesi, KA | 1 |
| Hartai, Z | 1 |
| Juhasz, G | 1 |
| Collado, JA | 2 |
| Medina, FJ | 3 |
| Peña, J | 3 |
| Del C Muñoz, M | 1 |
| Jimena, I | 3 |
| Franco, F | 2 |
| Rueda, I | 2 |
| Muntané, J | 2 |
| Price, J | 1 |
| Williams, SC | 1 |
| Modo, M | 1 |
| Drucker-Colín, R | 1 |
| Muñoz, Mdel C | 2 |
| Woodruff, TM | 1 |
| Crane, JW | 1 |
| Proctor, LM | 1 |
| Buller, KM | 1 |
| Shek, AB | 1 |
| de Vos, K | 1 |
| Pollitt, S | 1 |
| Williams, HM | 1 |
| Shiels, IA | 1 |
| Monk, PN | 1 |
| Taylor, SM | 1 |
| Padi, SS | 1 |
| Naidu, PS | 1 |
| Kang, L | 2 |
| Ko, SY | 1 |
| Prosperetti, C | 1 |
| De Chiara, V | 1 |
| Mataluni, G | 1 |
| Ayala, A | 1 |
| Venero, JL | 1 |
| Cano, J | 1 |
| Machado, A | 1 |
| Seo, H | 1 |
| Sonntag, KC | 1 |
| Kim, W | 1 |
| Isacson, O | 2 |
| Ramaswamy, S | 2 |
| Herzog, CD | 1 |
| Brandon, E | 1 |
| Gasmi, M | 1 |
| Bartus, RT | 1 |
| Huang, QY | 1 |
| Yu, L | 1 |
| Chen, JF | 1 |
| Hunter, JM | 1 |
| Lesort, M | 2 |
| Johnson, GV | 2 |
| Villanueva, M | 1 |
| Haynes, CL | 1 |
| Seipel, AT | 1 |
| Buhler, LA | 1 |
| Wightman, RM | 1 |
| Bemelmans, AP | 1 |
| Sindhu, KM | 1 |
| Sreetama, S | 1 |
| Kim, DH | 1 |
| Kim, S | 1 |
| Jung, SH | 1 |
| Kim, MW | 1 |
| Akashiba, H | 1 |
| Ikegaya, Y | 1 |
| Nishiyama, N | 1 |
| Matsuki, N | 1 |
| Dhir, A | 1 |
| Akula, KK | 1 |
| Kulkarni, SK | 1 |
| Zei, D | 1 |
| Palermo, R | 1 |
| Vacca, A | 1 |
| Borlongan, CV | 6 |
| Koutouzis, TK | 4 |
| Randall, TS | 2 |
| Freeman, TB | 3 |
| Cahill, DW | 4 |
| Dolan, R | 3 |
| Leroy-Willig, A | 1 |
| Palfi, S | 5 |
| Guyot, MC | 2 |
| Peschanski, M | 4 |
| Shimano, Y | 1 |
| Kumazaki, M | 1 |
| Sakurai, T | 1 |
| Hida, H | 1 |
| Fujimoto, I | 1 |
| Fukuda, A | 1 |
| Nishino, H | 2 |
| Galpern, WR | 1 |
| Matthews, RT | 2 |
| Maziére, M | 1 |
| Miller, PJ | 1 |
| Zaborszky, L | 1 |
| Kodsi, MH | 1 |
| Swerdlow, NR | 1 |
| Hauser, RA | 1 |
| Jenkins, BG | 1 |
| Rosen, BR | 1 |
| Kaddurah-Daouk, R | 1 |
| Reynolds, NC | 1 |
| Lin, W | 1 |
| Meyer Cameron, C | 1 |
| Roerig, DL | 1 |
| Condé, F | 4 |
| Riche, D | 1 |
| Dautry, C | 2 |
| Mittoux, V | 4 |
| Chibois, A | 1 |
| Reynolds, DS | 1 |
| Carter, RJ | 1 |
| Shear, DA | 1 |
| Dong, J | 1 |
| Gundy, CD | 1 |
| Haik-Creguer, KL | 1 |
| Bogdanov, MB | 1 |
| Kuemmerle, S | 1 |
| Andreassen, OA | 2 |
| Dedeoglu, A | 2 |
| Mueller, G | 1 |
| Lancelot, E | 1 |
| Bogdanov, M | 1 |
| Andersen, JK | 1 |
| Jiang, D | 1 |
| Vis, JC | 2 |
| Verbeek, MM | 2 |
| De Waal, RM | 2 |
| Ten Donkelaar, HJ | 2 |
| Kremer, HP | 1 |
| La Fontaine, MA | 1 |
| Banks, A | 2 |
| Altairac, S | 1 |
| Ménétrat, H | 1 |
| Joseph, JM | 1 |
| Poyot, T | 2 |
| Bloch, J | 1 |
| Nimchinsky, EA | 1 |
| Hof, PR | 1 |
| Aebischer, P | 1 |
| Storgaard, J | 1 |
| Kornblit, BT | 1 |
| Zimmer, J | 1 |
| Gramsbergen, JB | 1 |
| Hughes, DB | 1 |
| Ona, VO | 1 |
| Friedlander, RM | 1 |
| Fontaine, MA | 1 |
| Tucholski, J | 1 |
| Zhang, J | 1 |
| Hickey, MA | 1 |
| Rodrigues, CM | 2 |
| Stieers, CL | 1 |
| Keene, CD | 2 |
| Ma, X | 1 |
| Kren, BT | 2 |
| Low, WC | 2 |
| Steer, CJ | 2 |
| Canals, JM | 1 |
| Checa, N | 1 |
| Marco, S | 1 |
| Akerud, P | 1 |
| Michels, A | 1 |
| Pérez-Navarro, E | 1 |
| Tolosa, E | 1 |
| Arenas, E | 1 |
| Alberch, J | 1 |
| Yu, Z | 1 |
| Zhou, D | 1 |
| Cheng, G | 1 |
| Mattson, MP | 1 |
| Kremer, B | 1 |
| Greengard, P | 1 |
| Hipskind, RA | 1 |
| Borrelli, E | 1 |
| Fezza, F | 1 |
| Cebeira, M | 1 |
| Bisogno, T | 1 |
| Milone, A | 1 |
| Eich, T | 1 |
| Linehan-Stieers, C | 1 |
| Abt, A | 1 |
| El Massioui, N | 1 |
| Chéruel, F | 1 |
| Hansen, HH | 1 |
| Berrendero, F | 1 |
| Pérez-Rosado, A | 1 |
| Manzanares, J | 1 |
| Roitberg, BZ | 1 |
| Emborg, ME | 1 |
| Sramek, JG | 1 |
| Garcia, M | 1 |
| Vanhoutte, P | 1 |
| Pages, C | 1 |
| Besson, MJ | 1 |
| Caboche, J | 1 |
| Antonawich, FJ | 1 |
| Fiore-Marasa, SM | 1 |
| Parker, CP | 1 |
| Kwak, S | 1 |
| Monville, C | 1 |
| Lisovoski, F | 1 |
| Robichon, R | 1 |
| Sun, Z | 1 |
| Xie, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Coenzyme Q10 in Huntington's Disease (HD)[NCT00608881] | Phase 3 | 609 participants (Actual) | Interventional | 2008-03-31 | Terminated (stopped due to Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.) | ||
| Ursodiol in Huntington's Disease[NCT00514774] | Phase 1 | 21 participants (Anticipated) | Interventional | 2007-08-31 | Active, not recruiting | ||
| A Randomized, Double-blind Multicenter Pilot Study vs. Placebo for the Evaluation of Efficacy and Tolerability of Tauroursodeoxycholic Acid Administered by Oral Route as Add on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis[NCT00877604] | Phase 2 | 34 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 1.39 |
| B - Placebo | 1.43 |
The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 4.29 |
| B - Placebo | 5.06 |
"The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each yes reply and a score of 0 is given for each no reply (scale range is 0-25). Higher scores indicate better functioning." (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -7.93 |
| B - Placebo | -8.02 |
The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -26.30 |
| B - Placebo | -24.86 |
Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -14.21 |
| B - Placebo | -14.51 |
Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -7.57 |
| B - Placebo | -8.61 |
Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -15.25 |
| B - Placebo | -19.13 |
The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -10.95 |
| B - Placebo | -11.36 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -4.53 |
| B - Placebo | -4.76 |
The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 18.06 |
| B - Placebo | 19.18 |
The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -5.07 |
| B - Placebo | -4.47 |
The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
| Intervention | rank (Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 303.3 |
| B - Placebo | 306.7 |
(NCT00608881)
Timeframe: 5 years
| Intervention | participants completing study on drug (Number) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 98 |
| B - Placebo | 108 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
| Intervention | days to event (Median) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 917 |
| B - Placebo | 911 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
| Intervention | days to event (Median) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 553 |
| B - Placebo | 549 |
Responder patients were defined as those subjects showing an improvement of at least 15% in the ALSFRS-R slope during the treatment period as compared to the lead-in period. (NCT00877604)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| TUDCA | 13 |
| Placebo | 6 |
14 reviews available for 3-nitropropionic acid and Huntington Disease
| Article | Year |
|---|---|
An Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development.
Topics: Animals; Disease Models, Animal; Drug Discovery; Huntington Disease; Neurotoxins; Nitro Compounds; P | 2023 |
Exaggerated mitophagy: a weapon of striatal destruction in the brain?
Topics: Animals; Brain; Corpus Striatum; Drug Development; Hippocampus; Humans; Huntingtin Protein; Huntingt | 2020 |
3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington's disease: past, present and future.
Topics: Animals; Disease Models, Animal; Humans; Huntington Disease; Nitro Compounds; Propionates | 2010 |
Neuroprotective mechanisms of brain-derived neurotrophic factor against 3-nitropropionic acid toxicity: therapeutic implications for Huntington's disease.
Topics: Animals; Antioxidants; Brain; Brain-Derived Neurotrophic Factor; Cells, Cultured; Extracellular Sign | 2010 |
Magnetic resonance imaging and spectroscopy in assessing 3-nitropropionic acid-induced brain lesions: an animal model of Huntington's disease.
Topics: Animals; Brain; Convulsants; Disease Models, Animal; Humans; Huntington Disease; Magnetic Resonance | 2004 |
3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease.
Topics: Animals; Humans; Huntingtin Protein; Huntington Disease; Mitochondria; Neostriatum; Nerve Degenerati | 2005 |
Mitochondrial toxins and neurodegenerative diseases.
Topics: Animals; Disease Models, Animal; Humans; Huntington Disease; Mitochondria; MPTP Poisoning; Neurodege | 2007 |
Integrative hypothesis for Huntington's disease: a brief review of experimental evidence.
Topics: Animals; Calcium; Cell Death; Disease Models, Animal; Energy Metabolism; Excitatory Amino Acids; Hum | 2007 |
Animal models of Huntington's disease.
Topics: Animals; Disease Models, Animal; Disease Progression; Genetic Vectors; Huntington Disease; Lentiviru | 2007 |
Neurochemistry and toxin models in Huntington's disease.
Topics: Animals; Coenzymes; Disease Models, Animal; Energy Metabolism; Humans; Huntington Disease; Mitochond | 1994 |
Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antihypertensive Agents; Disease Models, Anim | 1995 |
3-Nitropropionic acid animal model and Huntington's disease.
Topics: Animals; Antihypertensive Agents; Disease Models, Animal; Huntington Disease; Nitro Compounds; Propi | 1997 |
Systemic, but not intraparenchymal, administration of 3-nitropropionic acid mimics the neuropathology of Huntington's disease: a speculative explanation.
Topics: Animals; Huntington Disease; Injections; Neostriatum; Nerve Degeneration; Neurotoxins; Nitro Compoun | 1997 |
[Huntington disease].
Topics: Animals; Corpus Striatum; Diagnosis, Differential; Humans; Huntingtin Protein; Huntington Disease; M | 2002 |
1 trial available for 3-nitropropionic acid and Huntington Disease
| Article | Year |
|---|---|
Erythropoietin and Bacillus Calmette-Guérin Vaccination Mitigate 3-Nitropropionic Acid-Induced Huntington-like Disease in Rats by Modulating the PI3K/Akt/mTOR/P70S6K Pathway and Enhancing the Autophagy.
Topics: Animals; Autophagy; BCG Vaccine; Erythropoietin; Huntington Disease; Male; Neuroprotective Agents; N | 2022 |
216 other studies available for 3-nitropropionic acid and Huntington Disease
| Article | Year |
|---|---|
Reduced mitochondrial complex II activity enhances cell death via intracellular reactive oxygen species in STHdhQ111 striatal neurons with mutant huntingtin.
Topics: Animals; Antioxidants; Cell Death; Edaravone; Electron Transport Complex II; Huntingtin Protein; Hun | 2021 |
Anti-Huntington's Effect of Butin in 3-Nitropropionic Acid-Treated Rats: Possible Mechanism of Action.
Topics: Animals; Behavior, Animal; Benzopyrans; Disease Models, Animal; Huntington Disease; Mice; Motor Acti | 2022 |
Telmisartan neuroprotective effects in 3-nitropropionic acid Huntington's disease model in rats: Cross talk between PPAR-γ and PI3K/Akt/GSK-3β pathway.
Topics: Animals; Glycogen Synthase Kinase 3 beta; Humans; Huntington Disease; Neuroprotective Agents; Nitro | 2022 |
Inosine attenuates 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats via the activation of the A2AR/BDNF/TrKB/ERK/CREB signaling pathway.
Topics: Animals; Brain-Derived Neurotrophic Factor; Complement Factor B; Cyclic AMP Response Element-Binding | 2022 |
Harmine prevents 3-nitropropionic acid-induced neurotoxicity in rats via enhancing NRF2-mediated signaling: Involvement of p21 and AMPK.
Topics: Adenylate Kinase; AMP-Activated Protein Kinases; Animals; Cyclin-Dependent Kinase Inhibitor p21; Har | 2022 |
Diapocynin neuroprotective effects in 3-nitropropionic acid Huntington's disease model in rats: emphasis on Sirt1/Nrf2 signaling pathway.
Topics: Acetophenones; Animals; bcl-2-Associated X Protein; Biphenyl Compounds; Brain-Derived Neurotrophic F | 2022 |
Berberine Ameliorate Haloperidol and 3-Nitropropionic Acid-Induced Neurotoxicity in Rats.
Topics: Animals; Antioxidants; Berberine; Catalase; Haloperidol; Huntington Disease; Motor Activity; Neuropr | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Filgrastim, a Recombinant Form of Granulocyte Colony-stimulating Factor, Ameliorates 3-nitropropionic Acid and Haloperidol-induced Striatal Neurotoxicity in Rats.
Topics: Animals; Filgrastim; Granulocyte Colony-Stimulating Factor; Haloperidol; Huntington Disease; Movemen | 2022 |
Glycyrrhizin prevents 3-nitropropionic acid-induced neurotoxicity by downregulating HMGB1/TLR4/NF-κB p65 signaling, and attenuating oxidative stress, inflammation, and apoptosis in rats.
Topics: Animals; Apoptosis; Body Weight; Glycyrrhizic Acid; HMGB1 Protein; Huntington Disease; Inflammation; | 2023 |
3-Nitropropionic Acid Enhances Ferroptotic Cell Death via NOX2-Mediated ROS Generation in STHdhQ111 Striatal Cells Carrying Mutant Huntingtin.
Topics: Animals; Caspases; Huntington Disease; Mice; Mice, Transgenic; Nerve Tissue Proteins; Neurodegenerat | 2023 |
Neuroprotectant Effects of Hibiscetin in 3-Nitropropionic Acid-Induced Huntington's Disease via Subsiding Oxidative Stress and Modulating Monoamine Neurotransmitters in Rats Brain.
Topics: Animals; Body Weight; Brain; Huntington Disease; Neuroprotective Agents; Neurotransmitter Agents; Ni | 2023 |
Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model.
Topics: Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dipeptidyl-Peptidase | 2020 |
Oxytocin protects against 3-NP induced learning and memory impairment in rats: Sex differences in behavioral and molecular responses to the context of prenatal stress.
Topics: Animals; Behavior, Animal; Brain; Cognitive Dysfunction; Conditioning, Operant; Disease Models, Anim | 2020 |
Ginsenoside Rg1 exerts neuroprotective effects in 3-nitropronpionic acid-induced mouse model of Huntington's disease via suppressing MAPKs and NF-κB pathways in the striatum.
Topics: Animals; Apoptosis; Corpus Striatum; Ginsenosides; Huntington Disease; Male; Mice; Mice, Inbred C57B | 2021 |
Potential role of TrkB agonist in neuronal survival by promoting CREB/BDNF and PI3K/Akt signaling in vitro and in vivo model of 3-nitropropionic acid (3-NP)-induced neuronal death.
Topics: Animals; Apoptosis; Brain-Derived Neurotrophic Factor; Cell Death; Cell Survival; Cyclic AMP Respons | 2021 |
Transplantation of human dental pulp stem cells compensates for striatal atrophy and modulates neuro-inflammation in 3-nitropropionic acid rat model of Huntington's disease.
Topics: Animals; Atrophy; Dental Pulp; Disease Models, Animal; Humans; Huntington Disease; Inflammation; Nit | 2021 |
A Novel Pharmacological Protective Role for Safranal in an Animal Model of Huntington's Disease.
Topics: Animals; Antioxidants; Behavior, Animal; Body Weight; Catalase; Cerebral Cortex; Cyclohexenes; Gluta | 2021 |
Elderberry diet ameliorates motor function and prevents oxidative stress-induced cell death in rat models of Huntington disease.
Topics: Animals; Cell Death; Disease Models, Animal; Electric Stimulation; Electromyography; Huntington Dise | 2021 |
Ellagic acid prevents 3-nitropropionic acid induced symptoms of Huntington's disease.
Topics: Animals; Catalase; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; El | 2021 |
Nano-ivabradine averts behavioral anomalies in Huntington's disease rat model via modulating Rhes/m-tor pathway.
Topics: Animals; Autophagy; Cardiovascular Agents; Corpus Striatum; Disease Models, Animal; Huntington Disea | 2021 |
Tert-buthylhydroquinone pre-conditioning exerts dual effects in old female rats exposed to 3-nitropropionic acid.
Topics: Animals; Cell Nucleus; Disease Models, Animal; Female; Huntington Disease; Hydroquinones; Neuroprote | 2017 |
3-NP-induced Huntington's-like disease impairs Nrf2 activation without loss of cardiac function in aged rats.
Topics: Animals; Antihypertensive Agents; Antioxidants; Female; Heart Diseases; Huntington Disease; Hydroqui | 2017 |
Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity.
Topics: Animals; Cannabis; Cell Line, Tumor; Disease Models, Animal; Dronabinol; Humans; Huntingtin Protein; | 2017 |
Neurotrophin-3 restores synaptic plasticity in the striatum of a mouse model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Male; Membrane Glycoproteins; | 2018 |
Human Umbilical Cord Matrix Stem Cells Reverse Oxidative Stress-Induced Cell Death and Ameliorate Motor Function and Striatal Atrophy in Rat Model of Huntington Disease.
Topics: Animals; Antigens, CD; Cell Death; Cell Differentiation; Cell Line; Convulsants; Cord Blood Stem Cel | 2018 |
Thymoquinone loaded solid lipid nanoparticles counteracts 3-Nitropropionic acid induced motor impairments and neuroinflammation in rat model of Huntington's disease.
Topics: Animals; Benzoquinones; Disease Models, Animal; Drug Delivery Systems; Encephalitis; Huntington Dise | 2018 |
Neuroprotective activity of tetramethylpyrazine against 3-nitropropionic acid induced Huntington's disease-like symptoms in rats.
Topics: Animals; Behavior, Animal; Catalase; Corpus Striatum; Glutathione; Hippocampus; Huntington Disease; | 2018 |
Nicotinamide reverses behavioral impairments and provides neuroprotection in 3-nitropropionic acid induced animal model ofHuntington's disease: implication of oxidative stress- poly(ADP- ribose) polymerase pathway.
Topics: Animals; Dose-Response Relationship, Drug; Huntington Disease; Male; Neuroprotection; Niacinamide; N | 2018 |
Cilostazol disrupts TLR-4, Akt/GSK-3β/CREB, and IL-6/JAK-2/STAT-3/SOCS-3 crosstalk in a rat model of Huntington's disease.
Topics: Animals; Apoptosis; Cilostazol; Corpus Striatum; CREB-Binding Protein; Cyclic AMP Response Element-B | 2018 |
Rutin and Selenium Co-administration Reverse 3-Nitropropionic Acid-Induced Neurochemical and Molecular Impairments in a Mouse Model of Huntington's Disease.
Topics: Animals; bcl-2-Associated X Protein; Brain-Derived Neurotrophic Factor; Caspase 3; Catalase; Corpus | 2020 |
Rhes deletion is neuroprotective in the 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Disease Models, Animal; Exploratory Behavior; GTP-Binding Proteins; Huntington Disease; Mic | 2013 |
Protective effect of Calendula officinalis Linn. flowers against 3-nitropropionic acid induced experimental Huntington's disease in rats.
Topics: Analysis of Variance; Animals; Body Weight; Calendula; Chromatography, High Pressure Liquid; Disease | 2013 |
Probucol increases striatal glutathione peroxidase activity and protects against 3-nitropropionic acid-induced pro-oxidative damage in rats.
Topics: Animals; Antioxidants; Catalase; Corpus Striatum; Drug Evaluation, Preclinical; Electron Transport C | 2013 |
Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington's disease.
Topics: Animals; Ataxia; Corpus Striatum; Curcumin; Disease Models, Animal; Drug Evaluation, Preclinical; Fe | 2014 |
Autophagy as a neuroprotective mechanism against 3-nitropropionic acid-induced murine astrocyte cell death.
Topics: Adenine; Animals; Apoptosis; Apoptosis Regulatory Proteins; Astrocytes; Autophagy; bcl-2-Associated | 2013 |
Neuroprotective effect of lutein against 3-nitropropionic acid-induced Huntington's disease-like symptoms: possible behavioral, biochemical, and cellular alterations.
Topics: Animals; Brain; Female; Glutathione; Humans; Huntington Disease; Lipid Peroxidation; Lutein; Maze Le | 2013 |
Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington's Disease.
Topics: Animals; Antioxidants; Astrocytes; Cell Proliferation; Cerebral Cortex; Corpus Striatum; Disease Mod | 2014 |
Circadian dysfunction in response to in vivo treatment with the mitochondrial toxin 3-nitropropionic acid.
Topics: Animals; Circadian Clocks; Convulsants; Gene Knock-In Techniques; Huntington Disease; Male; Mice; Mi | 2014 |
Role of neurosteroids in experimental 3-nitropropionic acid induced neurotoxicity in rats.
Topics: Animals; Behavior, Animal; Brain; Catalase; Glutathione; Huntington Disease; Interleukin-1beta; Lipi | 2014 |
Mitochondrial cofactors in experimental Huntington's disease: behavioral, biochemical and histological evaluation.
Topics: Acetylcarnitine; Animals; Antioxidants; Behavior, Animal; Brain; Chromatography, Thin Layer; Disease | 2014 |
Melatonin protects against behavioural dysfunctions and dendritic spine damage in 3-nitropropionic acid-induced rat model of Huntington's disease.
Topics: Animals; Convulsants; Dendritic Spines; Disease Models, Animal; Dose-Response Relationship, Drug; Dr | 2014 |
Pharmacological benefit of I(1)-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease.
Topics: Adrenergic Uptake Inhibitors; Animals; Anxiety; Brain; Disease Models, Animal; Ditiocarb; Huntington | 2014 |
Involvement of mGlu5 receptor in 3-nitropropionic acid-induced oxidative stress in rat striatum.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Exploratory Beha | 2014 |
Intrastriatal transplantation of adenovirus-generated induced pluripotent stem cells for treating neuropathological and functional deficits in a rodent model of Huntington's disease.
Topics: Adenoviridae; Animals; Behavior, Animal; Convulsants; Corpus Striatum; Disease Models, Animal; Femal | 2014 |
Protective effects of phosphodiesterase-1 (PDE1) and ATP sensitive potassium (KATP) channel modulators against 3-nitropropionic acid induced behavioral and biochemical toxicities in experimental Huntington׳s disease.
Topics: Animals; Female; Huntington Disease; KATP Channels; Male; Maze Learning; Motor Activity; Neostriatum | 2014 |
Pharmacological benefits of agomelatine and vanillin in experimental model of Huntington's disease.
Topics: Acetamides; Animals; Benzaldehydes; Disease Models, Animal; Female; Huntington Disease; Male; Maze L | 2014 |
The 3-NP Model of Striatal Neurodegeneration.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Male; Neurodegenerative Diseas | 2014 |
Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.
Topics: Animals; Brain; Cannabinoids; Disease Models, Animal; Huntington Disease; Male; Mice; Mice, Inbred C | 2015 |
Profilin-2 increased expression and its altered interaction with β-actin in the striatum of 3-nitropropionic acid-induced Huntington's disease in rats.
Topics: Actins; Animals; Cell Culture Techniques; Cerebral Cortex; Convulsants; Dendritic Spines; Disease Mo | 2014 |
Forkhead transcription factor FOXO3a levels are increased in Huntington disease because of overactivated positive autofeedback loop.
Topics: Animals; Blotting, Western; Cells, Cultured; Corpus Striatum; Feedback, Physiological; Female; Forkh | 2014 |
mRNA expression levels of PGC-1α in a transgenic and a toxin model of Huntington's disease.
Topics: Animals; Disease Models, Animal; Female; Gene Expression Regulation; Huntington Disease; Male; Mice, | 2015 |
Potential of protease inhibitor in 3-nitropropionic acid induced Huntington's disease like symptoms: mitochondrial dysfunction and neurodegeneration.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Female; Huntington Disease; Indoles; | 2014 |
Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington's disease.
Topics: Animals; Antioxidants; Basal Ganglia; Behavior, Animal; Disease Models, Animal; Dose-Response Relati | 2015 |
Neuroprotective potential of antioxidant potent fractions from Convolvulus pluricaulis Chois. in 3-nitropropionic acid challenged rats.
Topics: Animals; Antioxidants; Behavior, Animal; Body Weight; Convolvulus; Corpus Striatum; Glutathione; Hun | 2016 |
Mitochondrial modulators in experimental Huntington's disease: reversal of mitochondrial dysfunctions and cognitive deficits.
Topics: Acetylcarnitine; Animals; Cognition Disorders; Drug Therapy, Combination; Female; Huntington Disease | 2015 |
Mitochondrial modulators improve lipid composition and attenuate memory deficits in experimental model of Huntington's disease.
Topics: Acetylcarnitine; Animals; Behavior, Animal; Brain; Cholesterol; Chromatography, Thin Layer; Cognitio | 2015 |
Genistein improves sensorimotor gating: Mechanisms related to its neuroprotective effects on the striatum.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Apoptosis; Corpus Striatum; Dinoprostone; Disease Mod | 2016 |
Effect of embelin against 3-nitropropionic acid-induced Huntington's disease in rats.
Topics: Animals; Behavior, Animal; Benzoquinones; Body Weight; Brain; Catalase; Disease Models, Animal; Dose | 2016 |
L-theanine, a Component of Green Tea Prevents 3-Nitropropionic Acid (3-NP)-Induced Striatal Toxicity by Modulating Nitric Oxide Pathway.
Topics: Animals; Antioxidants; Corpus Striatum; Glutamates; Huntington Disease; Lipid Peroxidation; Male; Mo | 2017 |
Delayed Onset and Reduced Cognitive Deficits through Pre-Conditioning with 3-Nitropropionic Acid is Dependent on Sex and CAG Repeat Length in the R6/2 Mouse Model of Huntington's Disease.
Topics: Aging; Animals; Cognitive Dysfunction; Disease Models, Animal; Female; Humans; Huntington Disease; M | 2016 |
A novel therapeutic application of solid lipid nanoparticles encapsulated thymoquinone (TQ-SLNs) on 3-nitroproponic acid induced Huntington's disease-like symptoms in wistar rats.
Topics: Animals; Benzoquinones; Corpus Striatum; Disease Models, Animal; Drug Carriers; Huntington Disease; | 2016 |
Striatal mitochondria response to 3-nitropropionic acid and fish oil treatment.
Topics: Animals; Antioxidants; Corpus Striatum; Cytochrome-c Peroxidase; Disease Models, Animal; Dose-Respon | 2018 |
Chrysin exerts neuroprotective effects against 3-Nitropropionic acid induced behavioral despair-Mitochondrial dysfunction and striatal apoptosis via upregulating Bcl-2 gene and downregulating Bax-Bad genes in male wistar rats.
Topics: Animals; Apoptosis; Basal Ganglia; bcl-2-Associated X Protein; bcl-Associated Death Protein; Behavio | 2016 |
Effect of rutin against a mitochondrial toxin, 3-nitropropionicacid induced biochemical, behavioral and histological alterations-a pilot study on Huntington's disease model in rats.
Topics: Acetylcholinesterase; Animals; Antioxidants; Body Weight; Corpus Striatum; Glial Fibrillary Acidic P | 2017 |
Effect of Praeruptorin C on 3-nitropropionic acid induced Huntington's disease-like symptoms in mice.
Topics: Animals; Coumarins; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; | 2017 |
Ameliorating effect of Celastrus paniculatus standardized extract and its fractions on 3-nitropropionic acid induced neuronal damage in rats: possible antioxidant mechanism.
Topics: Animals; Antioxidants; Behavior, Animal; Biomarkers; Brain; Celastrus; Chromatography, Thin Layer; C | 2017 |
Mice deficient in L-12/15 lipoxygenase show increased vulnerability to 3-nitropropionic acid neurotoxicity.
Topics: Animals; Arachidonate 12-Lipoxygenase; Arachidonate 15-Lipoxygenase; Corpus Striatum; Disease Models | 2017 |
Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice.
Topics: Adenosine Triphosphate; Animals; Brain; Creatine; Female; Glucose; Glyceraldehyde-3-Phosphate Dehydr | 2008 |
Cell cycle activation in striatal neurons from Huntington's disease patients and rats treated with 3-nitropropionic acid.
Topics: Animals; Apoptosis; Cell Cycle Proteins; Convulsants; Corpus Striatum; Cyclin D1; Disease Models, An | 2008 |
Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease.
Topics: Animals; Cell Nucleus; Cerebral Cortex; Disease Models, Animal; DNA Damage; DNA, Mitochondrial; Guan | 2009 |
Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease.
Topics: Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, | 2008 |
Evidence of calpain/cdk5 pathway inhibition by lithium in 3-nitropropionic acid toxicity in vivo and in vitro.
Topics: Animals; Calcium; Calpain; Cell Survival; Cells, Cultured; Cyclin-Dependent Kinase 5; Disease Models | 2009 |
A role for oxidized DNA precursors in Huntington's disease-like striatal neurodegeneration.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Corpus Striatum; Deoxyguanosine; DNA Damage; DNA Repair Enzyme | 2008 |
Blood-brain barrier disruption in the striatum of rats treated with 3-nitropropionic acid.
Topics: Animals; Antigens, Surface; Basement Membrane; Blood-Brain Barrier; Corpus Striatum; Endothelium, Va | 2009 |
Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Lipid Peroxidation; Male; Meta | 2009 |
Metabonomic characterization of the 3-nitropropionic acid rat model of Huntington's disease.
Topics: Animals; Behavior, Animal; Brain; Brain Stem; Cerebellum; Cerebral Cortex; Choline; Corpus Striatum; | 2009 |
Cytochrome c oxidase isoform IV-2 is involved in 3-nitropropionic acid-induced toxicity in striatal astrocytes.
Topics: Adenosine Triphosphate; Animals; Astrocytes; Cell Survival; Cells, Cultured; Corpus Striatum; Electr | 2009 |
In vivo dopamine release and uptake impairments in rats treated with 3-nitropropionic acid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Central Nervous System Agents; Chroma | 2009 |
Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats.
Topics: Animals; Convulsants; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Respo | 2009 |
Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations.
Topics: Administration, Oral; Animals; Behavior, Animal; Brain; Brain Chemistry; Cholinesterase Inhibitors; | 2009 |
Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2'-Deoxyguanosine; alpha-Synuclein; Analysis | 2009 |
Sesamol attenuate 3-nitropropionic acid-induced Huntington-like behavioral, biochemical, and cellular alterations in rats.
Topics: Animals; Behavior, Animal; Benzodioxoles; Brain; Huntington Disease; Male; Molecular Structure; Nitr | 2009 |
Induction of heat shock protein 70 reduces the alteration of striatal electrical activity caused by mitochondrial impairment.
Topics: Animals; Corpus Striatum; Electron Transport Complex I; Electron Transport Complex II; Heat-Shock Re | 2009 |
Possible neuroprotective effect of Withania somnifera root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Huntington's disease.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Behavior, Animal; Brain; Catalase; Disease Models, An | 2009 |
CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington's disease.
Topics: Animals; Cells, Cultured; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Disease Mode | 2009 |
HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cell Death; Enzyme Inhibitors; Huntington Disease; Hypoxia-Inducible Fac | 2010 |
Kaempferol protects against rat striatal degeneration induced by 3-nitropropionic acid.
Topics: Animals; Calpain; Caspases; Convulsants; Corpus Striatum; Creatine Kinase; Disease Models, Animal; H | 2009 |
Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington's like symptoms in rats: possible role of nitric oxide.
Topics: Analysis of Variance; Animals; Antioxidants; Body Weight; Catalase; Corpus Striatum; Disease Models, | 2010 |
Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats.
Topics: Animals; Astrocytes; Basal Ganglia; Basal Ganglia Diseases; Behavior, Animal; Disability Evaluation; | 2010 |
Lycopene modulates nitric oxide pathways against 3-nitropropionic acid-induced neurotoxicity.
Topics: Animals; Anticarcinogenic Agents; Body Weight; Carotenoids; Catalase; Coloring Agents; Electron Tran | 2009 |
Promethazine protects against 3-nitropropionic acid-induced neurotoxicity.
Topics: Amyotrophic Lateral Sclerosis; Animals; Brain Ischemia; Disease Models, Animal; Huntington Disease; | 2010 |
Systemic administration of 3-nitropropionic acid points out a different role for active caspase-3 in neurons and astrocytes.
Topics: Animals; Apoptosis; Astrocytes; Caspase 3; Convulsants; Corpus Striatum; Disease Models, Animal; Enz | 2010 |
Altered open field behavior in rats induced by acute administration of 3-nitropropionic acid: possible glutamatergic and dopaminergic involvement.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Dopamine D2 | 2009 |
Novel protective mechanisms of antidepressants against 3-nitropropionic acid induced Huntington's-like symptoms: a comparative study.
Topics: Animals; Antidepressive Agents; Antioxidants; Brain; Huntington Disease; Male; Mitochondria; Motor A | 2011 |
Uncoupling oxidative/energy metabolism with low sub chronic doses of 3-nitropropionic acid or iodoacetate in vivo produces striatal cell damage.
Topics: Animals; Antioxidants; Apoptosis; Caspase 3; Corpus Striatum; Energy Metabolism; Huntington Disease; | 2010 |
Nitric oxide mechanism in the protective effect of antidepressants against 3-nitropropionic acid-induced cognitive deficit, glutathione and mitochondrial alterations in animal model of Huntington's disease.
Topics: Animals; Antidepressive Agents; Cognition Disorders; Convulsants; Disease Models, Animal; Dose-Respo | 2010 |
Possible nitric oxide modulation in protective effect of FK-506 against 3-nitropropionic acid-induced behavioral, oxidative, neurochemical, and mitochondrial alterations in rat brain.
Topics: Animals; Behavior, Animal; Body Weight; Brain; Brain Chemistry; Disease Models, Animal; Huntington D | 2010 |
Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.
Topics: Amino Acid Sequence; Animals; Cell Line, Tumor; Cytochromes c; Disease Models, Animal; Drosophila; E | 2010 |
Altered microRNA regulation in Huntington's disease models.
Topics: Animals; Chromosomes, Artificial, Yeast; Disease Models, Animal; Down-Regulation; Huntingtin Protein | 2011 |
Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: morphological and behavioral outcomes.
Topics: Animals; Behavior, Animal; Brain; Cell Differentiation; Cells, Cultured; Convulsants; Disease Models | 2011 |
Role of matrix metalloproteinase-9 (MMP-9) in striatal blood-brain barrier disruption in a 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Blood-Brain Barrier; Corpus Striatum; Disease Models, Animal; Huntington Disease; Immunohis | 2011 |
Preferential interneuron survival in the transition zone of 3-NP-induced striatal injury in rats.
Topics: Animals; Cell Survival; Corpus Striatum; Disease Models, Animal; Huntington Disease; Interneurons; M | 2011 |
Metabolic profiling of 3-nitropropionic acid early-stage Huntington's disease rat model using gas chromatography time-of-flight mass spectrometry.
Topics: Animals; Brain; Disease Models, Animal; Electron Transport Complex II; Galantamine; Gas Chromatograp | 2011 |
Worsening of Huntington disease phenotype in CB1 receptor knockout mice.
Topics: Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Disease Progression; Female; | 2011 |
Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington's disease-like symptoms in rats: protective effect of licofelone.
Topics: Animals; Antioxidants; Apoptosis; Behavior, Animal; Body Weight; Caspase 3; Corpus Striatum; Dinopro | 2011 |
NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Antagonists; Huntington Dise | 2011 |
FK506 ameliorates cell death features in Huntington's disease striatal cell models.
Topics: Animals; Apoptosis; Blotting, Western; Caspase 3; Cell Death; Cell Line; Corpus Striatum; Cytosol; D | 2011 |
Olive oil reduces oxidative damage in a 3-nitropropionic acid-induced Huntington's disease-like rat model.
Topics: Administration, Oral; Animals; Antioxidants; Corpus Striatum; Disease Models, Animal; Glutathione; H | 2011 |
The effect of Ginkgo biloba extract on 3-nitropropionic acid-induced neurotoxicity in rats.
Topics: Animals; Antioxidants; Disease Models, Animal; Down-Regulation; Ginkgo biloba; Huntington Disease; M | 2011 |
Lack of Jun-N-terminal kinase 3 (JNK3) does not protect against neurodegeneration induced by 3-nitropropionic acid.
Topics: Animals; Blotting, Western; Convulsants; Corpus Striatum; Disease Models, Animal; Enzyme Activation; | 2012 |
D-β-hydroxybutyrate is protective in mouse models of Huntington's disease.
Topics: 3-Hydroxybutyric Acid; Acetylation; Animals; Histones; Huntington Disease; Immunoblotting; Male; Mic | 2011 |
Early alterations of brain cellular energy homeostasis in Huntington disease models.
Topics: Adenosine Triphosphate; Animals; Brain Chemistry; Convulsants; Disease Models, Animal; Energy Metabo | 2012 |
Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity.
Topics: Amines; Animals; Body Weight; Brain; Catalase; Cyclohexanecarboxylic Acids; GABAergic Neurons; Gabap | 2012 |
Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro.
Topics: Animals; Antioxidants; Convulsants; Corpus Striatum; Disease Models, Animal; Huntington Disease; Lip | 2012 |
N-Acetylcysteine reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitropropionic acid-induced Huntington's disease.
Topics: Acetylcysteine; Animals; Behavior, Animal; Caspase 3; Cognition; Corpus Striatum; Female; Free Radic | 2012 |
Isoform-specific toxicity of Mecp2 in postmitotic neurons: suppression of neurotoxicity by FoxG1.
Topics: Animals; Animals, Newborn; Apoptosis; Cells, Cultured; Cerebellum; Disease Models, Animal; Female; F | 2012 |
pH as a biomarker of neurodegeneration in Huntington's disease: a translational rodent-human MRS study.
Topics: Adult; Animals; Antihypertensive Agents; Biomarkers; Corpus Striatum; Female; Humans; Huntington Dis | 2012 |
Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cation Transport Proteins; | 2013 |
Organoselenium bis selenide attenuates 3-nitropropionic acid-induced neurotoxicity in rats.
Topics: Animals; Ataxia; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Eva | 2013 |
hMTH1 expression protects mitochondria from Huntington's disease-like impairment.
Topics: Animals; Brain; Cell Death; Cell Line; Cells, Cultured; Disease Models, Animal; DNA Repair Enzymes; | 2013 |
Quercetin supplementation is effective in improving mitochondrial dysfunctions induced by 3-nitropropionic acid: implications in Huntington's disease.
Topics: Animals; Antioxidants; Catalase; Corpus Striatum; Dietary Supplements; Electron Transport Chain Comp | 2013 |
Heat shock transcription factor-1 suppresses apoptotic cell death and ROS generation in 3-nitropropionic acid-stimulated striatal cells.
Topics: Animals; Apoptosis; Caspase 3; Cell Line; Cell Survival; DNA-Binding Proteins; Gene Expression; Heat | 2013 |
MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms.
Topics: 3' Untranslated Regions; Animals; Apoptosis; Blotting, Western; Brain; Cell Survival; Cells, Culture | 2013 |
3-nitropropionic acid-induced changes in bilayer fluidity in synaptosomal membranes: implications for Huntington's disease.
Topics: Cell Membrane; Humans; Huntington Disease; Lipid Bilayers; Membrane Fluidity; Nitro Compounds; Oxida | 2002 |
Analysis of mitochondrial free radical generation in animal models of neuronal disease.
Topics: Adenosine Triphosphate; Animals; Brain Ischemia; Disease Models, Animal; Fluorescent Dyes; Free Radi | 2002 |
Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease.
Topics: Animals; Brain Chemistry; Cerebral Cortex; Chronic Disease; Corpus Striatum; Disease Models, Animal; | 2002 |
The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity.
Topics: Adenosine; Animals; Behavior, Animal; Binding, Competitive; Body Weight; Cerebral Cortex; Corpus Str | 2002 |
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acids, Neutral; Animals; Arachidonic Acids; Basal Ganglia; Can | 2003 |
Increased neuronal hypoxic tolerance induced by repetitive chemical hypoxia.
Topics: Adaptation, Physiological; Animals; Cell Hypoxia; Disease Models, Animal; Hippocampus; Huntington Di | 2002 |
Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons.
Topics: Animals; Apoptosis; Cell Nucleus; Cell Survival; Cells, Cultured; Cerebral Cortex; Disease Models, A | 2003 |
Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dependovirus; Disease Models, Animal; Genetic Therapy; G | 2003 |
Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease.
Topics: Acute Disease; Animals; Calpain; Caspases; Cell Death; Chronic Disease; Corpus Striatum; Disease Mod | 2003 |
A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists.
Topics: Adenosine; Animals; Body Weight; Cell Death; Corpus Striatum; Disease Models, Animal; Drug Administr | 2003 |
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington's disease.
Topics: Acetylcholine; Animals; Convulsants; Corpus Striatum; Dopamine; Excitatory Amino Acid Antagonists; g | 2003 |
Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.
Topics: Acetylation; Animals; Body Weight; Brain; Butyrates; Disease Models, Animal; Dose-Response Relations | 2003 |
Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease.
Topics: Acetates; Administration, Oral; Animals; Huntington Disease; Male; Mice; Mitochondria; Motor Activit | 2003 |
Effects of Sertoli cell transplants in a 3-nitropropionic acid model of early Huntington's disease: a preliminary study.
Topics: Animals; Behavior, Animal; Cerebral Ventricles; Huntington Disease; Immunohistochemistry; Male; Micr | 2003 |
Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms.
Topics: Animals; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; bcl-Associated Death Protein; Ca | 2004 |
Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease.
Topics: Acetylcholine; Adenosine Triphosphate; Animals; Cell Respiration; Dose-Response Relationship, Drug; | 2004 |
Inhibition of mitochondrial complex II alters striatal expression of genes involved in glutamatergic and dopaminergic signaling: possible implications for Huntington's disease.
Topics: Animals; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Electron Transport Complex II; Enz | 2004 |
Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Cell Count; Cerebral Cortex; | 2004 |
Experimental basis for the putative role of GluR6/kainate glutamate receptor subunit in Huntington's disease natural history.
Topics: Age of Onset; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Enzyme Inhibitors; | 2004 |
Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease.
Topics: Animals; Cells, Cultured; Convulsants; Corpus Striatum; Disease Models, Animal; Female; Huntington D | 2004 |
The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism.
Topics: Animals; Cell Death; Cells, Cultured; Disease Models, Animal; Enzyme Inhibitors; Farnesol; Huntingto | 2004 |
3-nitropropionic acid model of metabolic stress: assessment by magnetic resonance imaging.
Topics: Animals; Disease Models, Animal; Humans; Huntington Disease; Magnetic Resonance Imaging; Male; Nitro | 2005 |
Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease.
Topics: Animals; Antioxidants; Brain; Disease Models, Animal; Huntington Disease; Lipid Peroxidation; Male; | 2004 |
Minocycline in phenotypic models of Huntington's disease.
Topics: Animals; Calpain; Caspases; Cell Death; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Do | 2005 |
Altered distribution of striatal activity-dependent synaptic plasticity in the 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Enzyme Inhibitors; Huntington Disease; Immunohisto | 2005 |
Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease.
Topics: Animals; Brain Chemistry; Capsaicin; Convulsants; Disease Models, Animal; Dopamine; gamma-Aminobutyr | 2005 |
Neuroprotective effect of zVAD against the neurotoxin 3-nitropropionic acid involves inhibition of calpain.
Topics: Animals; Calpain; Carrier Proteins; Cell Death; Huntington Disease; Immunohistochemistry; Injections | 2005 |
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D | 2006 |
Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Down-R | 2005 |
Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons.
Topics: Acetylcholine; Animals; Behavior, Animal; Cholinergic Fibers; Convulsants; Disease Models, Animal; E | 2006 |
Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype.
Topics: Animals; Corpus Striatum; Disease Models, Animal; gamma-Aminobutyric Acid; Huntington Disease; Male; | 2005 |
Effects of mitochondrial toxins on the brain amino acid concentrations.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids; Animals; Brain Chemistry; Cerebral Cortex | 2005 |
17 beta-Estradiol may affect vulnerability of striatum in a 3-nitropropionic acid-induced experimental model of Huntington's disease in ovariectomized rats.
Topics: Animals; Apoptosis; Caspase 3; Caspases; Cell Survival; Convulsants; Corpus Striatum; Cytoprotection | 2006 |
Preservation of striatal tissue and behavioral function after neural stem cell transplantation in a rat model of Huntington's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Cell Line; Convulsants; Corpus Striatum; Disease Mo | 2006 |
Transcranial magnetic stimulation attenuates cell loss and oxidative damage in the striatum induced in the 3-nitropropionic model of Huntington's disease.
Topics: Animals; Catalase; Cell Count; Cell Death; Corpus Striatum; Disease Models, Animal; Glutathione; Hun | 2006 |
Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Huntington Disease; Ibuprofen; Male; Neurons; Neur | 2006 |
Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms.
Topics: Animals; Antioxidants; Behavior, Animal; Brain; Cell Survival; Glutathione; Huntington Disease; Inje | 2006 |
Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease.
Topics: Animals; Apoptosis Regulatory Proteins; Calpain; Cell Death; Corpus Striatum; Disease Models, Animal | 2006 |
Deficits of glutamate transmission in the striatum of toxic and genetic models of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Excitatory Postsynaptic Potentials; Glutamic Acid; | 2006 |
Effect of testosterone on oxidative stress and cell damage induced by 3-nitropropionic acid in striatum of ovariectomized rats.
Topics: Androgens; Animals; Cell Death; Corpus Striatum; Disease Models, Animal; Drug Antagonism; Female; Hu | 2007 |
Proteasome activator enhances survival of Huntington's disease neuronal model cells.
Topics: Cell Survival; Cells, Cultured; Corpus Striatum; Fibroblasts; Humans; Huntingtin Protein; Huntington | 2007 |
Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease.
Topics: Animals; Cell Count; Cell Death; Corpus Striatum; Cytoprotection; Dependovirus; Disease Models, Anim | 2007 |
Mutant SOD1G93A in bone marrow-derived cells exacerbates 3-nitropropionic acid induced striatal damage in mice.
Topics: Amyotrophic Lateral Sclerosis; Animals; Bone Marrow Cells; Bone Marrow Transplantation; Corpus Stria | 2007 |
Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease.
Topics: Cell Line; Corpus Striatum; Fluorescent Dyes; Genes, Reporter; Humans; Huntingtin Protein; Huntingto | 2007 |
Catecholamine exocytosis is diminished in R6/2 Huntington's disease model mice.
Topics: Adrenal Glands; Animals; Brain; Catecholamines; Chromaffin Cells; Convulsants; Disease Models, Anima | 2007 |
IGF-1 exacerbates the neurotoxicity of the mitochondrial inhibitor 3NP in rats.
Topics: Animals; Cell Death; Cell Survival; Convulsants; Corpus Striatum; Disease Models, Animal; Dose-Respo | 2007 |
Mitochondrial NAD+-linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Body Weight; Cerebral Cortex; Citrate (si)-Synthase | 2008 |
Granulocyte-colony stimulating factor attenuates striatal degeneration with activating survival pathways in 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Drug Interactions; Fluoresceins; Gene Expression R | 2008 |
Differential involvement of cell cycle reactivation between striatal and cortical neurons in cell death induced by 3-nitropropionic acid.
Topics: Animals; Calcium Signaling; Calpain; Cell Death; Cerebral Cortex; Convulsants; Corpus Striatum; Cycl | 2008 |
Tiagabine, a GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats.
Topics: Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; Dose-Response Relationship, Drug | 2008 |
NF-kB/NOS cross-talk induced by mitochondrial complex II inhibition: implications for Huntington's disease.
Topics: Active Transport, Cell Nucleus; Animals; Cell Line, Tumor; Electron Transport Complex II; Enzyme Inh | 2008 |
Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats.
Topics: Animals; Avoidance Learning; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Histocytoche | 1995 |
Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates.
Topics: Animals; Behavior, Animal; Chorea; Corpus Striatum; Energy Metabolism; Histocytochemistry; Huntingto | 1995 |
Asymmetrical motor behavior in rats with unilateral striatal excitotoxic lesions as revealed by the elevated body swing test.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Functional Laterali | 1995 |
Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Injections, Intraperitoneal; M | 1995 |
Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease.
Topics: Animals; Apomorphine; Behavior, Animal; Brain; Cognition; Huntington Disease; Movement; Neurotoxins; | 1996 |
Chronically administered 3-nitropropionic acid produces selective lesions in the striatum and reduces muscle tonus.
Topics: Animals; Complement C3b; Complement C4b; Corpus Striatum; Digestive System; Enzyme Inhibitors; Glial | 1995 |
NGF attenuates 3-nitrotyrosine formation in a 3-NP model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Male; Nerve Growth Factors; Ni | 1996 |
Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid.
Topics: Analysis of Variance; Animals; Corpus Striatum; Dihydrolipoamide Dehydrogenase; Drug Administration | 1997 |
3-Nitropropionic acid neurotoxicity: visualization by silver staining and implications for use as an animal model of Huntington's disease.
Topics: Animals; Brain; Caudate Nucleus; Coloring Agents; Disease Models, Animal; Dose-Response Relationship | 1997 |
Mitochondrial toxin 3-nitropropionic acid produces startle reflex abnormalities and striatal damage in rats that model some features of Huntington's disease.
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Hunting | 1997 |
Hyperactivity and hypoactivity in a rat model of Huntington's disease: the systemic 3-nitropropionic acid model.
Topics: Animals; Behavior, Animal; Drug Administration Schedule; Huntington Disease; Injections, Intraperito | 1997 |
Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease.
Topics: Adenosine Triphosphate; Animals; Antihypertensive Agents; Antineoplastic Agents; Creatine; Creatinin | 1998 |
Differential responses of extracellular GABA to intrastriatal perfusions of 3-nitropropionic acid and quinolinic acid in the rat.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Enzyme Inhibitors; Excitatory Amino Acid Agonists; | 1997 |
Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease.
Topics: Animals; Apomorphine; Brain Tissue Transplantation; Cognition; Corpus Striatum; Fetal Tissue Transpl | 1998 |
Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease.
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Benzazepines; Corpus Striatum; Disease Models, A | 1998 |
Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease.
Topics: Animals; Cerebral Ventricles; Corpus Striatum; Disease Models, Animal; Electron Transport Complex IV | 1998 |
Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease.
Topics: Animals; Corpus Striatum; Drug Resistance; Huntington Disease; Hydroxybenzoates; Hydroxyl Radical; M | 1998 |
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 2000 |
3-Nitropropionic acid induces a spectrum of Huntington's disease-like neuropathology in rat striatum.
Topics: Animals; Corpus Striatum; gamma-Aminobutyric Acid; Glial Fibrillary Acidic Protein; Hindlimb; Huntin | 1999 |
3-nitropropionic acid induced in vivo protein oxidation in striatal and cortical synaptosomes: insights into Huntington's disease.
Topics: Animals; Blotting, Western; Cerebral Cortex; Convulsants; Corpus Striatum; Cyclic N-Oxides; Huntingt | 2000 |
Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies.
Topics: Animals; Behavior, Animal; Cell Survival; Convulsants; Disease Models, Animal; Drug Administration R | 2000 |
Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease.
Topics: Animals; Brain; Calbindins; Cell Line; Ciliary Neurotrophic Factor; Convulsants; Cricetinae; Disease | 2000 |
3-Nitropropionic acid neurotoxicity in organotypic striatal and corticostriatal slice cultures is dependent on glucose and glutamate.
Topics: Animals; Aspartic Acid; Cells, Cultured; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; D | 2000 |
Malonate and 3-nitropropionic acid neurotoxicity are reduced in transgenic mice expressing a caspase-1 dominant-negative mutant.
Topics: Animals; Brain; Caspase 1; Crosses, Genetic; Disease Models, Animal; Female; Huntington Disease; Mal | 2000 |
Effect of exogenous and endogenous antioxidants on 3-nitropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington's disease.
Topics: Acetylcysteine; Animals; Antioxidants; Cerebral Cortex; Corpus Striatum; Cyclic N-Oxides; Electron S | 2000 |
Impaired mitochondrial function results in increased tissue transglutaminase activity in situ.
Topics: Adenosine Triphosphate; Antioxidants; Calcium; Dose-Response Relationship, Drug; GTP-Binding Protein | 2000 |
Mice transgenic for the Huntington's disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity.
Topics: Aging; Animals; Behavior, Animal; Body Weight; Corpus Striatum; Crosses, Genetic; Diabetes Mellitus; | 2000 |
Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspases; Cells, Cultured; Cytochrome c Group; Hepat | 2000 |
Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area.
Topics: 3T3 Cells; Animals; Axonal Transport; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Colchicine | 2001 |
Neuroprotective role for the p50 subunit of NF-kappaB in an experimental model of Huntington's disease.
Topics: Animals; Apoptosis; Calcium; Cell Survival; Cells, Cultured; Convulsants; Disease Models, Animal; Fe | 2000 |
The mitochondrial toxin 3-nitropropionic acid induces differential expression patterns of apoptosis-related markers in rat striatum.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Corpus Striatum; Disease Models, Animal; Gene Expres | 2001 |
Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Infusion Pumps; Injections, Su | 2001 |
Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine.
Topics: Animals; Calcium Channel Blockers; Chelating Agents; Corpus Striatum; Dopamine; Electric Stimulation | 2001 |
Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease.
Topics: Animals; Basal Ganglia; Cannabinoid Receptor Modulators; Cannabinoids; Convulsants; Disease Models, | 2001 |
A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Cell Death; Cells, Cultured; Cognition; Corpus Striatum; Disease Models, Animal; Female; Hu | 2001 |
A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Cell Death; Cells, Cultured; Cognition; Corpus Striatum; Disease Models, Animal; Female; Hu | 2001 |
A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Cell Death; Cells, Cultured; Cognition; Corpus Striatum; Disease Models, Animal; Female; Hu | 2001 |
A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Cell Death; Cells, Cultured; Cognition; Corpus Striatum; Disease Models, Animal; Female; Hu | 2001 |
Perseverative behavior underlying attentional set-shifting deficits in rats chronically treated with the neurotoxin 3-nitropropionic acid.
Topics: Animals; Attention; Behavior, Animal; Cognition; Corpus Striatum; Discrimination Learning; Disease M | 2001 |
Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cannabinoids; Convulsants; Disease Mode | 2002 |
Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease.
Topics: Animals; Brain Mapping; Caudate Nucleus; Cebus; Disease Models, Animal; Frontal Lobe; Humans; Huntin | 2002 |
The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase/c-Jun module.
Topics: Active Transport, Cell Nucleus; Animals; Apoptosis; Cells, Cultured; Corpus Striatum; Disease Models | 2002 |
Modulation of apoptotic regulatory proteins and early activation of cytochrome C following systemic 3-nitropropionic acid administration.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Behavior, Animal; Convulsants; Cytoch | 2002 |
Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration.
Topics: Adenoviridae; Animals; Behavior, Animal; Cell Count; Cell Survival; Cerebral Cortex; Ciliary Neurotr | 2002 |
The differential vulnerability of striatal projection neurons in 3-nitropropionic acid-treated rats does not match that typical of adult-onset Huntington's disease.
Topics: Animals; Cell Survival; Corpus Striatum; Disease Models, Animal; Entopeduncular Nucleus; Globus Pall | 2002 |